British Journal of Pharmacology
November 25, 2021
Éva Borbély, Mária Simon, Eberhard Fuchs et al.
103 citations
Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment‐resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1) knowledge of pathophysiology, (2) translational animal models and (3) objective diagnostic...
Frontiers in Psychiatry
November 24, 2021
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch et al.
47 citations
Research over the last two decades has established ketamine as a safe, effective, fast-acting, and sustained antidepressant that significantly reduces adverse symptoms associated with depression, even in patients who are treatment resistant. Much of this research has evolved within the framework of several independent branches of scientific inquiry: in addition to the study of ketamine is a...
Scientific Reports
November 18, 2021
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey et al.
78 citations
Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers ( n = 4050) and non-microdosers ( n = 4653) via a mobile application. Psilocybin was the most commonly...
CNS Drugs
November 17, 2021
Susan Ling, Felicia Ceban, Leanna M.W. Lui et al.
123 citations
Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and...
Journal of adolescence
November 14, 2021
Melanie J Zimmer-Gembeck, Sarah J Clear, Shawna M Campbell
Introduction: Adolescents higher in the trait of dispositional mindfulness report fewer socioemotional problems. Focusing on the domain of peer stressors, we tested a model of adolescents' mindfulness as a resource that undergirds more constructive stress coping responses, in turn resulting in fewer socioemotional problems. Method: The participants were 361 Australian secondary school students...
Depression and Anxiety
November 9, 2021
J. D. de Klerk-Sluis, Marloes J. Huijbers, S. Löcke et al.
Mindfulness‐based cognitive therapy (MBCT) is effective for relapse prevention in major depressive disorder (MDD). It reduces cognitive reactivity (CR) and rumination, and enhances self‐compassion and mindfulness. Although rumination and mindfulness after MBCT are associated with relapse, the association of CR, rumination, self‐compassion, and mindfulness with relapse before initiation of MBCT...
Scholarly Research In Progress
November 8, 2021
Sankung X. Darboe, Peter J. Koszuta, Paul W. Lee et al.
The anesthetic agent ketamine has been under investigation as a potential antidepressant for two decades. Animal studies and subsequent randomized control trials for patients have provided extensive evidence of ketamine’s rapid antidepressant outcomes both structurally at the receptor level as well as behaviorally. A review of current literature hones in on the putative rapid mechanisms of...
Translational Psychiatry
November 8, 2021
Manoj K. Doss, Michal Považan, Monica D Rosenberg et al.
343 citations
Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity. Recent studies have proposed neuropsychoplastogenic effects as mechanisms underlying the enduring therapeutic effects of psilocybin. In an open-label study of 24 patients with major depressive disorder, we tested the enduring effects of psilocybin...
Life
November 5, 2021
Mateusz Kowalczyk, Edward Kowalczyk, Paweł Kwiatkowski et al.
16 citations
The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the...
International Journal of Community Music
November 1, 2021
Emily Foulkes
It is reported that COVID-19 has had a significant impact on increasing mental health problems and exacerbating existing mental health conditions. The aim was to explore the potential of an online singing and mindfulness programme for people with anxiety and/or depression. Seven participants were socially prescribed to a nine-week programme of online singing and mindfulness delivered by the...